Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.

Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P  =  .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P  =  .002) were significantly higher among patients with 25(OH)D level of ≤20 vs  20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs  ≥30 ng/mL (P  =  .0001).

Study details: Findings are from a retrospective study including 233 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368

Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.

Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P  =  .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P  =  .002) were significantly higher among patients with 25(OH)D level of ≤20 vs  20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs  ≥30 ng/mL (P  =  .0001).

Study details: Findings are from a retrospective study including 233 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368

Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.

Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P  =  .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P  =  .002) were significantly higher among patients with 25(OH)D level of ≤20 vs  20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs  ≥30 ng/mL (P  =  .0001).

Study details: Findings are from a retrospective study including 233 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368

Key clinical point: Women with endometriosis seemed prone to migraine, with menstrual-related migraine being the most common type and dysmenorrhea and dysuria being more frequent when endometriosis and migraine coexisted.

Major finding: Overall, 53.4% of women had migraine, of which 64.3% had migraine related to menstruation and 35.7% had non-menstrual migraine. Typical endometriosis-related pain symptoms such as dysmenorrhea (94.3% vs 82.0%; P  =  .03) and dysuria (27.1% vs 9.8%; P < .01) occurred significantly more frequently in patients with vs without migraine.

Study details: This was a prospective, nested case-control study including 131 women with endometriosis with or without migraine.

Disclosures: This study was supported by a grant from Ministero della Salute, Italy. The authors declared no conflicts of interest.

Source: Pasquini B, Seravalli V, et al. Endometriosis and the diagnosis of different forms of migraine: an association with dysmenorrhea. Reprod Biomed Online. 2023 (Apr 6). Doi: 10.1016/j.rbmo.2023.03.020

Key clinical point: Women with endometriosis seemed prone to migraine, with menstrual-related migraine being the most common type and dysmenorrhea and dysuria being more frequent when endometriosis and migraine coexisted.

Major finding: Overall, 53.4% of women had migraine, of which 64.3% had migraine related to menstruation and 35.7% had non-menstrual migraine. Typical endometriosis-related pain symptoms such as dysmenorrhea (94.3% vs 82.0%; P  =  .03) and dysuria (27.1% vs 9.8%; P < .01) occurred significantly more frequently in patients with vs without migraine.

Study details: This was a prospective, nested case-control study including 131 women with endometriosis with or without migraine.

Disclosures: This study was supported by a grant from Ministero della Salute, Italy. The authors declared no conflicts of interest.

Source: Pasquini B, Seravalli V, et al. Endometriosis and the diagnosis of different forms of migraine: an association with dysmenorrhea. Reprod Biomed Online. 2023 (Apr 6). Doi: 10.1016/j.rbmo.2023.03.020

Key clinical point: Women with endometriosis seemed prone to migraine, with menstrual-related migraine being the most common type and dysmenorrhea and dysuria being more frequent when endometriosis and migraine coexisted.

Major finding: Overall, 53.4% of women had migraine, of which 64.3% had migraine related to menstruation and 35.7% had non-menstrual migraine. Typical endometriosis-related pain symptoms such as dysmenorrhea (94.3% vs 82.0%; P  =  .03) and dysuria (27.1% vs 9.8%; P < .01) occurred significantly more frequently in patients with vs without migraine.

Study details: This was a prospective, nested case-control study including 131 women with endometriosis with or without migraine.

Disclosures: This study was supported by a grant from Ministero della Salute, Italy. The authors declared no conflicts of interest.

Source: Pasquini B, Seravalli V, et al. Endometriosis and the diagnosis of different forms of migraine: an association with dysmenorrhea. Reprod Biomed Online. 2023 (Apr 6). Doi: 10.1016/j.rbmo.2023.03.020

Key clinical point: Migraine diagnosis was not significantly correlated with a higher frequency of an absence of ischemic penumbra, its volume, or the prognosis of ischemic stroke.

Major finding: There was no significant association between migraine diagnosis and the absence of ischemic penumbra (P  =  .649), stroke volume (P  =  .995), or prognosis of ischemic stroke.

Study details: Findings are from a prospective cohort study including 221 patients with ischemic stroke who were hospitalized within 72 hours of the onset of symptoms, of which 59 had migraine.

Disclosures: The study was financed in part by the Coordenaçao de Aperfeiçoamento de Pessoal de Nível Superior-Brasil. The authors declared no conflicts of interest.

Source: Oliveira FAA et al. Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study. Headache. 2023;63:549-558 (Mar 29). Doi: 10.1111/head.14492

Key clinical point: Migraine diagnosis was not significantly correlated with a higher frequency of an absence of ischemic penumbra, its volume, or the prognosis of ischemic stroke.

Major finding: There was no significant association between migraine diagnosis and the absence of ischemic penumbra (P  =  .649), stroke volume (P  =  .995), or prognosis of ischemic stroke.

Study details: Findings are from a prospective cohort study including 221 patients with ischemic stroke who were hospitalized within 72 hours of the onset of symptoms, of which 59 had migraine.

Disclosures: The study was financed in part by the Coordenaçao de Aperfeiçoamento de Pessoal de Nível Superior-Brasil. The authors declared no conflicts of interest.

Source: Oliveira FAA et al. Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study. Headache. 2023;63:549-558 (Mar 29). Doi: 10.1111/head.14492

Key clinical point: Migraine diagnosis was not significantly correlated with a higher frequency of an absence of ischemic penumbra, its volume, or the prognosis of ischemic stroke.

Major finding: There was no significant association between migraine diagnosis and the absence of ischemic penumbra (P  =  .649), stroke volume (P  =  .995), or prognosis of ischemic stroke.

Study details: Findings are from a prospective cohort study including 221 patients with ischemic stroke who were hospitalized within 72 hours of the onset of symptoms, of which 59 had migraine.

Disclosures: The study was financed in part by the Coordenaçao de Aperfeiçoamento de Pessoal de Nível Superior-Brasil. The authors declared no conflicts of interest.

Source: Oliveira FAA et al. Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study. Headache. 2023;63:549-558 (Mar 29). Doi: 10.1111/head.14492

Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.

Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs  axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).

Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).

Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.

Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.

Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.

Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs  axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).

Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).

Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.

Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.

Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.

Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs  axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).

Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).

Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.

Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.

Key clinical point: Fremanezumab demonstrated early and sustained efficacy with an optimal safety profile in patients with high disability and high-frequency episodic migraine (HFEM) or chronic migraine (CM) with multiple preventive failures and diverse comorbidities.

Major finding: At 21-24 weeks, fremanezumab significantly reduced monthly migraine days in patients with HFEM (−6.9 ± 3.6; P < .001) and monthly headache days in patients with CM (−14.2 ± 7.6; P < .001) along with significant reductions in monthly analgesic medications and Numerical Rating Scale scores in both patients with HFEM and CM (P < .001), with benefits sustaining throughout treatment period and adverse events being rare.

Study details: This multicenter, prospective real-life study included 148 patients with migraine (HFEM, n = 52; CM, n = 96) who were treated with fremanezumab for ≥24 weeks.

Disclosures: The study was partially supported by the Italian Ministry of Health Institutional Funding Ricerca Corrente San Raffaele Roma, Italy. Some authors declared receiving research support, travel grants, or honoraria for advisory board participation, speaking, or clinical investigation studies from various sources.

Source: Barbanti P et al for the FRIEND-Study Group. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: The multicenter, prospective, real-life FRIEND2 study. J Headache Pain. 2023;24:30 (Mar 23). Doi: 10.1186/s10194-023-01561-w

Key clinical point: Fremanezumab demonstrated early and sustained efficacy with an optimal safety profile in patients with high disability and high-frequency episodic migraine (HFEM) or chronic migraine (CM) with multiple preventive failures and diverse comorbidities.

Major finding: At 21-24 weeks, fremanezumab significantly reduced monthly migraine days in patients with HFEM (−6.9 ± 3.6; P < .001) and monthly headache days in patients with CM (−14.2 ± 7.6; P < .001) along with significant reductions in monthly analgesic medications and Numerical Rating Scale scores in both patients with HFEM and CM (P < .001), with benefits sustaining throughout treatment period and adverse events being rare.

Study details: This multicenter, prospective real-life study included 148 patients with migraine (HFEM, n = 52; CM, n = 96) who were treated with fremanezumab for ≥24 weeks.

Disclosures: The study was partially supported by the Italian Ministry of Health Institutional Funding Ricerca Corrente San Raffaele Roma, Italy. Some authors declared receiving research support, travel grants, or honoraria for advisory board participation, speaking, or clinical investigation studies from various sources.

Source: Barbanti P et al for the FRIEND-Study Group. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: The multicenter, prospective, real-life FRIEND2 study. J Headache Pain. 2023;24:30 (Mar 23). Doi: 10.1186/s10194-023-01561-w

Key clinical point: Fremanezumab demonstrated early and sustained efficacy with an optimal safety profile in patients with high disability and high-frequency episodic migraine (HFEM) or chronic migraine (CM) with multiple preventive failures and diverse comorbidities.

Major finding: At 21-24 weeks, fremanezumab significantly reduced monthly migraine days in patients with HFEM (−6.9 ± 3.6; P < .001) and monthly headache days in patients with CM (−14.2 ± 7.6; P < .001) along with significant reductions in monthly analgesic medications and Numerical Rating Scale scores in both patients with HFEM and CM (P < .001), with benefits sustaining throughout treatment period and adverse events being rare.

Study details: This multicenter, prospective real-life study included 148 patients with migraine (HFEM, n = 52; CM, n = 96) who were treated with fremanezumab for ≥24 weeks.

Disclosures: The study was partially supported by the Italian Ministry of Health Institutional Funding Ricerca Corrente San Raffaele Roma, Italy. Some authors declared receiving research support, travel grants, or honoraria for advisory board participation, speaking, or clinical investigation studies from various sources.

Source: Barbanti P et al for the FRIEND-Study Group. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: The multicenter, prospective, real-life FRIEND2 study. J Headache Pain. 2023;24:30 (Mar 23). Doi: 10.1186/s10194-023-01561-w

Key clinical point: The odds of having migraine with or without aura is higher among patients with migraine with vs without inflammatory bowel disease (IBD); however, patients with migraine and IBD are less likely to have chronic migraine or receive treatment for migraine.

Major finding: Patients with migraine with vs without IBD were more likely to have migraine with (odds ratio [OR] 2.20; P < .001) and without (OR 2.79; P < .001) aura, but were less likely to have chronic migraine (OR 0.23; P < .001) or receive treatment for migraine (OR 0.23-0.55; P ≤ .037).

Study details: Findings are from a retrospective cohort study including 675 patients with migraine, of which 280 patients had IBD.

Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.

Source: Sileno SM et al. Comparison of migraine characteristics in patients with and without inflammatory bowel disease: A retrospective cohort study. J Prim Care Community Health. 2023 (Mar 23). Doi: 10.1177/21501319231164307

Key clinical point: The odds of having migraine with or without aura is higher among patients with migraine with vs without inflammatory bowel disease (IBD); however, patients with migraine and IBD are less likely to have chronic migraine or receive treatment for migraine.

Major finding: Patients with migraine with vs without IBD were more likely to have migraine with (odds ratio [OR] 2.20; P < .001) and without (OR 2.79; P < .001) aura, but were less likely to have chronic migraine (OR 0.23; P < .001) or receive treatment for migraine (OR 0.23-0.55; P ≤ .037).

Study details: Findings are from a retrospective cohort study including 675 patients with migraine, of which 280 patients had IBD.

Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.

Source: Sileno SM et al. Comparison of migraine characteristics in patients with and without inflammatory bowel disease: A retrospective cohort study. J Prim Care Community Health. 2023 (Mar 23). Doi: 10.1177/21501319231164307

Key clinical point: The odds of having migraine with or without aura is higher among patients with migraine with vs without inflammatory bowel disease (IBD); however, patients with migraine and IBD are less likely to have chronic migraine or receive treatment for migraine.

Major finding: Patients with migraine with vs without IBD were more likely to have migraine with (odds ratio [OR] 2.20; P < .001) and without (OR 2.79; P < .001) aura, but were less likely to have chronic migraine (OR 0.23; P < .001) or receive treatment for migraine (OR 0.23-0.55; P ≤ .037).

Study details: Findings are from a retrospective cohort study including 675 patients with migraine, of which 280 patients had IBD.

Disclosures: This study did not receive any funding. The authors declared no potential conflicts of interest.

Source: Sileno SM et al. Comparison of migraine characteristics in patients with and without inflammatory bowel disease: A retrospective cohort study. J Prim Care Community Health. 2023 (Mar 23). Doi: 10.1177/21501319231164307

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs  without CA (8.82 vs  8.54; P  =  .002) or CAP (8.88 vs  8.55; P  =  .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride‑glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs  without CA (8.82 vs  8.54; P  =  .002) or CAP (8.88 vs  8.55; P  =  .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride‑glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs  without CA (8.82 vs  8.54; P  =  .002) or CAP (8.88 vs  8.55; P  =  .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride‑glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Key clinical point: Patients with migraine are at a higher risk of developing subsequent primary open angle glaucoma (POAG), with the risk being even higher among patients with chronic and severe migraine.

Major finding: Over 9 years of follow-up, the incidence rates of POAG were 3.249 and 2.408 per 1000 person-years in patients with and without migraine, respectively. Compared with individuals without migraine, patients with migraine and severe migraine had 1.19 (adjusted HR [aHR] 1.188; 95% CI 1.140-1.239) and 1.29 (aHR 1.285; 95% CI 1.166-1.415) times higher risk for POAG, respectively.

Study details: Findings are from a retrospective cohort study including 2,716,562 individuals aged ≥40 years, of which 87,809 had migraine.

Disclosures: The study was funded by Catholic Medical Center Research Foundation, New Hampshire. The authors declared no competing interests.

Source: Ohn K et al. Presence and severity of migraine is associated with development of primary open angle glaucoma: A population-based longitudinal cohort study. PLoS One. 2023;18(3):e0283495 (Mar 24). Doi: 10.1371/journal.pone.0283495

Key clinical point: Patients with migraine are at a higher risk of developing subsequent primary open angle glaucoma (POAG), with the risk being even higher among patients with chronic and severe migraine.

Major finding: Over 9 years of follow-up, the incidence rates of POAG were 3.249 and 2.408 per 1000 person-years in patients with and without migraine, respectively. Compared with individuals without migraine, patients with migraine and severe migraine had 1.19 (adjusted HR [aHR] 1.188; 95% CI 1.140-1.239) and 1.29 (aHR 1.285; 95% CI 1.166-1.415) times higher risk for POAG, respectively.

Study details: Findings are from a retrospective cohort study including 2,716,562 individuals aged ≥40 years, of which 87,809 had migraine.

Disclosures: The study was funded by Catholic Medical Center Research Foundation, New Hampshire. The authors declared no competing interests.

Source: Ohn K et al. Presence and severity of migraine is associated with development of primary open angle glaucoma: A population-based longitudinal cohort study. PLoS One. 2023;18(3):e0283495 (Mar 24). Doi: 10.1371/journal.pone.0283495

Key clinical point: Patients with migraine are at a higher risk of developing subsequent primary open angle glaucoma (POAG), with the risk being even higher among patients with chronic and severe migraine.

Major finding: Over 9 years of follow-up, the incidence rates of POAG were 3.249 and 2.408 per 1000 person-years in patients with and without migraine, respectively. Compared with individuals without migraine, patients with migraine and severe migraine had 1.19 (adjusted HR [aHR] 1.188; 95% CI 1.140-1.239) and 1.29 (aHR 1.285; 95% CI 1.166-1.415) times higher risk for POAG, respectively.

Study details: Findings are from a retrospective cohort study including 2,716,562 individuals aged ≥40 years, of which 87,809 had migraine.

Disclosures: The study was funded by Catholic Medical Center Research Foundation, New Hampshire. The authors declared no competing interests.

Source: Ohn K et al. Presence and severity of migraine is associated with development of primary open angle glaucoma: A population-based longitudinal cohort study. PLoS One. 2023;18(3):e0283495 (Mar 24). Doi: 10.1371/journal.pone.0283495

Key clinical point: Ultrasound-guided stellate ganglion blockade (SGB) is a safe and effective treatment option for patients with chronic migraine (CM); however, comorbid anxiety, or depression negatively predict SGB efficacy.

Major finding: The effective rates of ultrasound-guided SGB treatment were 90.7%, 82.5%, and 71.1% at 1-, 2-, and 3-month follow-ups, respectively, with the number of SGB being significantly greater in patients who did vs did not respond to SGB at the 3-month follow-up (P  =  .02) and comorbid anxiety or depression being a negative predictor of poor response to SGB (B −0.25; P  =  .01). Overall, the SGB-associated adverse event rate was 9.3%, with all adverse events being transient.

Study details: The data come from a retrospective, single-center study including 97 patients with CM who received ≥1 ultrasound-guided SGB treatment with a time interval of 1-7 days.

Disclosures: The study funded by The Capital’s Funds for Health Improvement and Research, China. The authors declared no conflicts of interest.

Source: Yu B et al. Effectiveness, safety, and predictors of response to ultrasound-guided stellate ganglion blockades for the treatment of patients with chronic migraine: A retrospective and observational study. Pain Pract. 2023 (Mar 16). Doi: 10.1111/papr.13224

Key clinical point: Ultrasound-guided stellate ganglion blockade (SGB) is a safe and effective treatment option for patients with chronic migraine (CM); however, comorbid anxiety, or depression negatively predict SGB efficacy.

Major finding: The effective rates of ultrasound-guided SGB treatment were 90.7%, 82.5%, and 71.1% at 1-, 2-, and 3-month follow-ups, respectively, with the number of SGB being significantly greater in patients who did vs did not respond to SGB at the 3-month follow-up (P  =  .02) and comorbid anxiety or depression being a negative predictor of poor response to SGB (B −0.25; P  =  .01). Overall, the SGB-associated adverse event rate was 9.3%, with all adverse events being transient.

Study details: The data come from a retrospective, single-center study including 97 patients with CM who received ≥1 ultrasound-guided SGB treatment with a time interval of 1-7 days.

Disclosures: The study funded by The Capital’s Funds for Health Improvement and Research, China. The authors declared no conflicts of interest.

Source: Yu B et al. Effectiveness, safety, and predictors of response to ultrasound-guided stellate ganglion blockades for the treatment of patients with chronic migraine: A retrospective and observational study. Pain Pract. 2023 (Mar 16). Doi: 10.1111/papr.13224

Key clinical point: Ultrasound-guided stellate ganglion blockade (SGB) is a safe and effective treatment option for patients with chronic migraine (CM); however, comorbid anxiety, or depression negatively predict SGB efficacy.

Major finding: The effective rates of ultrasound-guided SGB treatment were 90.7%, 82.5%, and 71.1% at 1-, 2-, and 3-month follow-ups, respectively, with the number of SGB being significantly greater in patients who did vs did not respond to SGB at the 3-month follow-up (P  =  .02) and comorbid anxiety or depression being a negative predictor of poor response to SGB (B −0.25; P  =  .01). Overall, the SGB-associated adverse event rate was 9.3%, with all adverse events being transient.

Study details: The data come from a retrospective, single-center study including 97 patients with CM who received ≥1 ultrasound-guided SGB treatment with a time interval of 1-7 days.

Disclosures: The study funded by The Capital’s Funds for Health Improvement and Research, China. The authors declared no conflicts of interest.

Source: Yu B et al. Effectiveness, safety, and predictors of response to ultrasound-guided stellate ganglion blockades for the treatment of patients with chronic migraine: A retrospective and observational study. Pain Pract. 2023 (Mar 16). Doi: 10.1111/papr.13224

Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) are an effective treatment option for vestibular migraine (VM), with a large proportion of patients showing simultaneous reduction in migraine days, vertigo days, and Migraine Disability Assessment (MIDAS) score.

Major finding: At 12 months after CGRP mAb treatment, the mean monthly dizziness/vestibular symptom days (mean difference [MD] 9.5 days), headache frequency (MD 13.8 days), and MIDAS score (MD 36.1) were significantly reduced in the overall cohort (P < .001) and 78% of patients showed ≥50% reduction in all 3 parameters.

Study details: Findings are from a prospective observational cohort study including 50 patients with chronic migraine who met the criteria for VM and were treated with fremanezumab (n = 25), galcanezumab (n = 18), or erenumab (n = 7).

Disclosures: This study did not receive any funding. CV Russo, F Sacca, and R De Simone declared receiving personal compensation, public speaking honoraria, or consulting fees from various sources.

Source: Russo CV et al. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study. Cephalalgia. 2023;43(4):3331024231161809 (Mar 22). Doi: 10.1177/03331024231161809

Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) are an effective treatment option for vestibular migraine (VM), with a large proportion of patients showing simultaneous reduction in migraine days, vertigo days, and Migraine Disability Assessment (MIDAS) score.

Major finding: At 12 months after CGRP mAb treatment, the mean monthly dizziness/vestibular symptom days (mean difference [MD] 9.5 days), headache frequency (MD 13.8 days), and MIDAS score (MD 36.1) were significantly reduced in the overall cohort (P < .001) and 78% of patients showed ≥50% reduction in all 3 parameters.

Study details: Findings are from a prospective observational cohort study including 50 patients with chronic migraine who met the criteria for VM and were treated with fremanezumab (n = 25), galcanezumab (n = 18), or erenumab (n = 7).

Disclosures: This study did not receive any funding. CV Russo, F Sacca, and R De Simone declared receiving personal compensation, public speaking honoraria, or consulting fees from various sources.

Source: Russo CV et al. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study. Cephalalgia. 2023;43(4):3331024231161809 (Mar 22). Doi: 10.1177/03331024231161809

Key clinical point: Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) are an effective treatment option for vestibular migraine (VM), with a large proportion of patients showing simultaneous reduction in migraine days, vertigo days, and Migraine Disability Assessment (MIDAS) score.

Major finding: At 12 months after CGRP mAb treatment, the mean monthly dizziness/vestibular symptom days (mean difference [MD] 9.5 days), headache frequency (MD 13.8 days), and MIDAS score (MD 36.1) were significantly reduced in the overall cohort (P < .001) and 78% of patients showed ≥50% reduction in all 3 parameters.

Study details: Findings are from a prospective observational cohort study including 50 patients with chronic migraine who met the criteria for VM and were treated with fremanezumab (n = 25), galcanezumab (n = 18), or erenumab (n = 7).

Disclosures: This study did not receive any funding. CV Russo, F Sacca, and R De Simone declared receiving personal compensation, public speaking honoraria, or consulting fees from various sources.

Source: Russo CV et al. Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study. Cephalalgia. 2023;43(4):3331024231161809 (Mar 22). Doi: 10.1177/03331024231161809